Trombolyysiä

Trombolyysi, also known as thrombolytic therapy, is a medical treatment that aims to dissolve blood clots. Blood clots, or thrombi, can form in blood vessels and obstruct blood flow, leading to various serious health conditions such as heart attack, stroke, and deep vein thrombosis. Trombolyysi works by administering medications called thrombolytics, which are also referred to as "clot-busting" drugs. These medications activate plasminogen, a protein in the blood, which then converts into plasmin. Plasmin is an enzyme that breaks down fibrin, a protein that forms the meshwork of a blood clot.

The administration of trombolyysi is typically done intravenously, meaning the medication is injected directly into a vein. The specific drug used and the duration of treatment depend on the type and severity of the condition being treated, as well as the patient's overall health. While effective in restoring blood flow and preventing tissue damage, trombolyysi also carries risks, primarily an increased risk of bleeding. This is because the same mechanism that dissolves the problematic clot can also affect normal blood clotting processes. Therefore, trombolyysi is administered under close medical supervision, and patients are carefully screened for contraindications, such as recent surgery or a history of bleeding disorders. The decision to use trombolyysi involves weighing the potential benefits against these risks.